FDA
BioInvent Receives FDA Orphan Designation for BI-1206 for Mantle Cell Lymphoma
BioInvent
PR-M01-19-NI-088Jan 30, 2019
Drug Designation
Martin Pharmaceuticals’ LIVANTRA™ Receives FDA Orphan Drug Designation in Second Indication
Martin Pharmaceuticals
PR-M09-18-NI-033Sep 13, 2018
FDA Orphan Drug Designation
Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis
Pliant Therapeutics
PR-M08-18-NI-058Aug 15, 2018
Orphan Drug
Processa Pharmaceuticals Receives Orphan Designation Status For PCS499 In Necrobiosis Lipoidica From The Food And Drug Administration (FDA)
Processa Pharmaceuticals, Inc.
PR-M06-18-NI-079Jun 25, 2018
Orphan Drug
Samus Therapeutics Announces PU-H71 Granted Orphan Drug Designation and First Patient Dosed in Phase 1b Study in Myelofibrosis
Samus Therapeutics
PR-M06-18-NI-050Jun 14, 2018
Drug Designation
Genea Biocells Announces FDA Orphan Drug Designation for GBC0905 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
Genea Biocells
PR-M06-18-NI-016Jun 06, 2018